Dr. Francesco M. Marincola, M.D., F.A.C.S.
Chief Scientific Officer – TAM Global
Francesco M. Marincola, M.D., is a legend and pioneer in tumor immunology whose transformative contributions have shaped the field of immunotherapy and translational medicine. As the founder and Editor-in-Chief of the Journal of Translational Medicine, past President of the Society for Immunotherapy of Cancer (2013-2014), and former Chief of Infectious Disease and Immunogenetics at the National Institutes of Health (NIH) in Bethesda, Maryland, Dr. Marincola has been at the forefront of advancing cancer research and therapeutic innovation.
Currently serving as Chief Scientific Officer of TAM Global, Dr. Marincola leads strategic efforts to develop novel oncology therapeutics and oversee the vast array of scientific research. With an M.D. from the University of Milan (cum laude, 1978), he completed surgical oncology training at Stanford University and held pivotal roles at the NIH, including Tenured Senior Investigator and Director of the Immunogenetics Program. His prior leadership positions include Senior VP and Global Head of Research at Kite Pharma, President and CSO at Refuge Biotechnologies, and Chief Research Officer at Sidra Medical and Research Centre in Qatar.
Dr. Marincola’s groundbreaking work in melanoma and immunotherapy has earned him global recognition, including being the second most cited scientist in melanoma over a decade. He has authored over 600 peer-reviewed publications, holds prestigious awards such as the 2020 SITC Visionary/Legacy Award, and serves on numerous scientific advisory boards. A mentor to emerging scientists, he has fostered innovation through roles like Chairman of international symposia and advisor to institutions worldwide.
At the TAM Center, Dr. Marincola’s visionary leadership and unparalleled expertise continue to drive pioneering advancements in tumor immunology and translational medicine, shaping the future of cancer treatment.
Dr. Ali Asadi, Ph.D.
Chief Innovation Officer – TAM Global
Ali Asadi is a highly accomplished scientific leader and the Chief Innovation Officer at TAM Global, recognized for his pioneering contributions to chemistry, diagnostics, and therapeutics. From co-founding Iran’s first neonatal screening program and an associated patient support NGO to establishing large-scale manufacturing of essential medicines, Mr. Asadi has consistently translated scientific vision into tangible impact.
His pursuit of scientific excellence led to a PhD in Organic Chemistry from the University of British Columbia and significant research at the Scripps Research Institute, including foundational work in nanopore sequencing. At Illumina, Mr. Asadi was instrumental in the development of their first proteomics product and the groundbreaking FDA-approved TSO-500 pan-cancer companion diagnostic. His innovative spirit is further evidenced by patented technologies in epigenetic analysis and key manufacturing processes.
Holding a double master’s degree and an MBA, Mr. Asadi brings a unique blend of scientific depth and business insight to his role at TAM Global. As Chief Innovation Officer, he is committed to driving the development of advanced personalized diagnostics, oligonucleotides, and peptide therapeutics to benefit patients.
Dr. Vijay Mahant, MS, Ph.D
Chief Technology Officer – TAM Global
Dr. Mahant graduated from LUT in the United Kingdom and received his second post-doctorate from MD Anderson in Houston TX. Dr. Mahant is a scientist with over 30 years of experience in immune and molecular diagnostics. He has held executive positions, and he is the founder/co-founder of diagnostic companies with diverse experiences in Research and Development, including Auto Genomics, Medi-Lite, and Qualigen. He is the inventor of the “New Generation” ultra-sensitive TSH test for prostate cancer.
Dr. Mahant’s work can be seen all over the world in leading cancer institutions using his cutting edge genetic and diagnostic equipment. He has been on the forefront of the liquid biopsy and circulating tumor cell movement. His passion is to find ways to match tumors with specific drugs that might be off label and to create even better early detection diagnostic tests.
Diego Guerena, Ph.D.
President – TAM Global
Dr. Diego Guerena, PhD, is a powerhouse in the fields of diagnostics and genomics, blending his deep-rooted scientific expertise with a keen sense of entrepreneurship. His journey, spanning the vibrant landscapes of Mexico and the United States, has been marked by groundbreaking contributions that have significantly advanced the integration of translational medicine into clinical practice.
After earning his Ph.D. in Biotechnology from the prestigious Universidad Autonoma de Madrid, Spain, Diego has been at the helm of various transformative projects. Notably, he spearheaded the development of an accredited biotech lab in Baja, Mexico, producing influential research and commercial outputs that continue to resonate within the scientific community. His strategic move to Mexico City further highlighted his prowess, where he led pivotal diagnostics and biotechnology initiatives for Laboratorios Silanes, a leading name in Mexico’s pharmaceutical sector.
Diego’s tenure at Pathway Genomics Corp, now OME Care, in San Diego, was particularly instrumental, where he undertook the ambitious task of establishing the first sequencing lab in Tijuana. His efforts in setting clinical benchmarks for genetic testing and navigating the complex regulatory landscape underscore his resilience and commitment to innovation. Despite encountering challenges, including a significant building violation that jeopardized the project, Diego’s determination and skillful navigation through adversity were evident as he successfully pivoted towards enhancing consumer-focused clinical genomic studies.
His visionary approach didn’t stop at the borders of the U.S.; Diego expanded his influence across Latin America, forging vital networks and collaborations that leveraged sequencing technologies, clinical certifications, and AI to redefine clinical genomics.
Following the acquisition of Pathway Genomics Diego co-founded LSG Clinicos, establishing state-of-the-art reference laboratories across Mexico that specialize in molecular and clinical chemistry testing.
Diego also channeled his expertise into Purpose Health, LLC, directing groundbreaking work in sequencing the oral microbiome and biomarkers. His 25-year tenure in biotechnology is distinguished by a result-oriented approach, optimizing laboratory functions, adhering to stringent regulatory standards, and leading multidisciplinary teams towards shared goals.of NGS in clinical settings underscores his ongoing commitment to enhancing healthcare through biotechnological advancements.
Dr. Erik Hett, Ph.D.
Chief Technology Officer – TAM Biosciences
Erik C. Hett, Ph.D., is a visionary drug development leader with a distinguished career in driving scientific strategy and therapeutic innovation across large pharma and biotech. With a Ph.D. in Immunology and Infectious Diseases from Harvard University, an M.P.H. in Biostatistics and Epidemiology from Yale University, and a B.S. in Biological Sciences from Montana State University (summa cum laude), Dr. Hett combines deep scientific expertise with strategic acumen to deliver transformative solutions.
Dr. Hett spearheads the design and execution of our oncology discovery platform, delivering novel insights, targets, and lead therapeutics across modalities such as mRNA, oncolytic viruses, and small molecules. He has built a multifunctional team integrating data science, machine learning, molecular biology, and in vivo capabilities while driving a small molecule program toward clinical stages. Previously, at Merck’s Exploratory Sciences Center, he led a team of over 30 scientists, developed novel proximity labeling technology, and spun out a company focused on antibody-drug conjugates. His earlier roles at Biogen and Pfizer involved pioneering chemical biology approaches for target identification and mechanism of action studies, contributing to clinical programs in hematology, neuroscience, and kinase inhibition.
Dr. Hett’s postdoctoral work at Massachusetts General Hospital, Broad Institute, and Harvard Medical School elucidated inflammasome-mediated pathways, laying the groundwork for his leadership in chemical biology. A prolific innovator, he holds multiple patents, has published 35 peer-reviewed articles in journals like Nature Chemical Biology and Science, and has delivered invited talks at global symposia. His honors include the Ruth L. Kirschstein NIH Fellowship, Pfizer’s W.E. Upjohn Prize, and co-founding the ChemBio in the Hub Symposium.
Dr. Hett has also served on advisory boards for Tufts University and the Chemical Probes Portal. At the TAM Center, he uses his years of experience to advance cutting-edge therapeutic research and platform development as Chief Technology Officer.
Jocelynn Pearl, Ph.D.
Director of Therapeutic Development – TAM Center
Jocelynn Pearl, Ph.D., is a molecular and cellular biologist with over a decade of experience developing cutting-edge therapies for oncology, CNS, and autoimmune disorders. She received her undergraduate degree from the University of California at Berkeley and her Ph.D. from the University of Washington and the Institute for Systems Biology in 2017.
Her dissertation examined systems genomics approaches for understanding transcription factor networks in several neurological disorders. Previously, Dr. Pearl worked on some of the first gene and epigenome editing programs at Sangamo BioSciences (2010-2013).
She engineered epigenome editors to counteract T Cell exhaustion during a postdoctoral fellowship at Altius Institute (2017-2019), and went on to engineer novel CAR T cells at Lyell Immunopharma.
She then worked to advance epigenome engineering towards the clinic at Tune Therapeutics in Seattle, WA, from 2020-2024. Her passion lies in developing next-generation therapies for devastating illnesses for which there is no cure.
Dr. Joyce Hu, Ph.D.
VP, Cancer Biology -TAM Biosciences
Joyce Hu, Ph.D., is a seasoned immunologist and research leader with 18 years of expertise in developing innovative platforms and therapeutics across modalities, including cell therapy, mRNA-based treatments, and small molecules. She earned her Ph.D. in Immunology from the University of California, San Francisco, and a B.A. in Music from the University of California, Berkeley. Renowned for her leadership of multidisciplinary teams, Dr. Hu excels in fostering collaborative cultures, promoting continuous learning, and driving scientific advancements in cancer and infectious disease research.
As Vice President and Head of Cancer Biology Dr. Hu leads a team focused on building a cutting-edge oncology platform, developing assays for target characterization using in vitro and in vivo methods, and advancing drug development in small molecules and mRNA therapeutics. She collaborates with leadership in drug discovery, strategy, business development, finance, and HR to achieve corporate goals. Previously, as Site Head of Research at BioNTech US, she spearheaded personalized and off-the-shelf TCR-T and CAR-T cell therapies for solid tumors, setting research strategies and timelines. At Kite Pharma, she led biomarker and T cell discovery, utilizing multi-omics and high-throughput mRNA synthesis platforms, while her work at Adaptive Biotechnologies and Poseida Therapeutics advanced TCR identification and CAR-T cell engineering.
Dr. Hu’s postdoctoral research at the La Jolla Institute for Allergy and Immunology contributed to HIV vaccine strategies and cancer vaccine development, while her doctoral work elucidated chemokine and S1P receptor roles in CD8 T cell differentiation. She has published extensively in journals such as Nature Immunology, PNAS, and Journal of Experimental Medicine, holds a patent on TCR identification, and has delivered invited talks at prestigious conferences like the HIV Vaccines Keystone Symposia. Her grant-writing efforts have secured over $3.5 million in funding, including NIH and industry grants.
A dedicated mentor and reviewer for top-tier journals, Dr. Hu brings exceptional organizational and communication skills to the TAM Center, where her leadership continues to drive transformative advancements in cancer biology and therapeutic innovation.
Dr. Kevin P. Clancy, Ph.D.
Director of Genomics – TAM Center
Dr. Kevin P. Clancy stands out in the genomics field, combining a robust academic background with a flair for translating complex biological data into impactful clinical solutions. His journey began with a Ph.D. in Clinical Biochemistry from the University of Cambridge, focusing on transcript analysis in the rat CNS, and an honors degree in Biochemistry from Queens University Belfast, setting the stage for a career at the intersection of science and patient care.
Dr. Clancy’s professional story is marked by significant strides in product development and management, particularly at ThermoFisher and in his development of a translational genomics platform at SGI. His tenure at Invitae and Myriad Genetics is notable for his leadership in software development, contributing to the release of cutting-edge medical devices and enhancing the functionality of clinical laboratory products.
A master of collaboration, Dr. Clancy’s ability to work seamlessly with executive teams and thought leaders has led to the creation of novel genomic tools and influential publications. His tenure has been especially transformative in improving data-sharing protocols and advancing electronic health records systems.
Dr. Clancy’s expertise extends to the intricate world of complex bioinformatics systems, where his innovative approaches have streamlined processes and elevated data analysis. His technical skills cover a broad spectrum, including various programming languages, machine and deep learning techniques, data management strategies, and software development architectures. This versatility underlines his comprehensive grasp of the genomic landscape.
As a dynamic force in genomics, Dr. Clancy continues to ignite change and progress, blending his deep scientific understanding with an enthusiasm for pioneering new paths in medicine and patient care. His career is a testament to the power of bridging research with real-world applications, making a tangible difference in the ever-evolving field of genomics.
Dr. Patricia Juárez
Director of Stem Cell Therapies – TAM Center
Dr. Juarez is a group leader and tenured researcher in the Department of Biomedical Innovation at CICESE. She completed her Ph.D. in Biochemical Sciences at UNAM and her postdoctoral training at the University of Virginia and Indiana University. Her research group focused on the study and treatment of metastatic bone cancer caused by solid tumors and the study of bone remodeling agents for the treatment of degenerative bone diseases. Using in vitro and in vivo models and nanotechnology.
She has been the recipient of various awards, including the Rising star Award from the American Society for Bone and Mineral Research (ASBMR) in the USA in 2016, and the Young Investigator Award from the International Bone and Mineral Society, and the Young Investigator Award at the 12th International Conference on Cancer-Induced Bone Disease. Lyon, Fr. in 2012, and the John Haddad Young Investigator Award. Snowmass, CO. By the AIMM/ASBMR.
She sits on the board of directors for the Cancer and Bone Society since 2014.
Dr. Juarez actively participated in various international committees of the ASBMR such as Women in Bone, MEEC educational committee, and currently the finance committee. In 2019 she was named ASBMR ambassador for Mexico. She has been a member of the Education Committee of the International Federation of Musculoskeletal Research Society since 2020. She has also been a member of the scientific committee of the Asociación Mexicana de Metabolismo Oseo y Mineral (AMMOM) since 2021, and in the same year, she was honored by being named a member of the Mexican Academy of Science. In 2022, she was appointed executive president of AMMOM.
From 2019-2022, she served as the director of the post-graduate studies program in Life Sciences at CICESE and taught courses at CNYN-UNAM and CICESE. She has directed the thesis of 20 postgraduate students, including masters and doctoral degrees.
Patricia is SNI-II, has published 36 peer reviewed articles, and 4 book chapters, her work has received 1122 citations (Scopus) and she has an IMPI invention patent application for her work on Europium-doped Gadolinium oxide nanoparticles functionalized with folic acid and its use for real-time detection of cancer cells in vivo.
Dr. Sabin Dhakal, Ph.D
Principal Scientist, Cancer Biology – TAM Bioscience
Sabin Dhakal, Ph.D., is a distinguished cancer biologist with extensive expertise in oncology, functional genomics, and preclinical drug development. Dr. Dhakal earned his Ph.D. in Biological and Biomedical Sciences with a concentration in Cancer Biology from Harvard University, where his thesis focused on functional heterogeneity in triple-negative breast cancer (TNBC). He also holds a secondary concentration in Science, Technology, and Society from Harvard Kennedy School and a B.A. in Biology and Chemistry from Hanover College, with a minor in Mathematics.
As a Principal Scientist at Sonata Therapeutics, Dr. Dhakal served as lead inventor on five major patent applications and has been instrumental in establishing the company’s ISG-based and genome-wide screening platforms for oncology target identification. He leads biology efforts for oncolytic virus- and mRNA-based programs, advises on small molecule and Genetic Switch initiatives, and contributes to strategic R&D decisions.
Dr. Dhakal’s postdoctoral work at Harvard Medical School explored immunogenic interferon signaling in TNBC, while his doctoral research in the Joan Brugge Laboratory established novel models to study intratumoral heterogeneity and drug resistance. Earlier, at Dana-Farber Cancer Institute, he utilized functional genomics to identify novel oncogenes and metastasis drivers in melanoma and glioblastoma. His work has been published in high-impact journals, including Nature, Cancer Cell, and Cell Metabolism.
A recipient of the Harvard Graduate Fellowship and multiple Hanover College awards, Dr. Dhakal is also an experienced mentor, having guided Harvard undergraduate and graduate students. He has delivered keynote seminars at prestigious institutions, including the New York Academy of Sciences and the Bill and Melinda Gates Medical Research Institute. At the TAM Center, Dr. Dhakal’s innovative leadership continues to drive transformative advancements in cancer research and therapeutic development.
Dr. Wenlong Xu, Ph.D.
Principal Scientist, Molecular Oncology – TAM Bioscience
Wenlong Xu, Ph.D., is a distinguished synthetic biologist with over a decade of academic and industrial experience in developing data-driven platforms that integrate high-throughput molecular cloning, functional genomics, quantitative characterization, advanced data analysis, and machine learning. His innovative work in genome-wide screening, cancer target discovery, AAV gene therapy, and mammalian synthetic biology has been published in prestigious journals, establishing him as a pioneer in addressing fundamental and therapeutic challenges.
Dr. Xu earned his Ph.D. in Chemical Engineering from Colorado State University, where he conducted groundbreaking research on synthetic genetic circuits and intracellular mechanics. He completed his postdoctoral training at MIT’s Synthetic Biology Center, focusing on genetic circuits for liver organoid maturation and programmable genetic neural networks. Currently, as Director of Molecular Oncology at a leading therapeutics company, Dr. Xu leads cross-functional teams to develop next-generation target discovery platforms, leveraging mammalian synthetic biology and machine learning to drive drug discovery programs. His previous roles include advancing AAV gene therapy at Biogen and developing novel biotechnologies to overcome gene therapy challenges.
Skilled in experimental techniques such as CRISPR library screening, modRNA in vitro transcription, and next-generation sequencing, as well as computational methods including machine learning and stochastic modeling, Dr. Xu combines technical expertise with strategic leadership. Proficient in Python, Matlab, and C++, he excels in managing multifunctional teams, mentoring talent, and delivering ambitious projects under stringent timelines. His contributions have earned him accolades, including the NSF IGERT Fellowship and multiple patents.
Passionate about advancing platform biology and quantitative methods, Dr. Xu’s work at the TAM Center continues to push the boundaries of synthetic biology and therapeutic innovation.
Dr. Gianni Monaco
Principal Scientist, Cancer Bioinformatics – TAM Biosciences
Gianni Monaco is an accomplished scientist and data analyst with extensive experience in immuno-oncology, multi-omics and single-cell technologies. With a strong background in both computational biology and wet-lab, Gianni has contributed significantly to the development of analytical tools and the interpretation of high-dimensional biological data.
Gianni holds a Bachelor’s degree in Biology and a Master’s degree in Genetics and Biotechnologies. He earned his PhD in Life Sciences from the University of Liverpool through a joint program with the Agency for Science, Technology and Research (A*STAR) in Singapore. In 2018, he joined the University Hospital of Basel as a researcher, and in 2021, he was awarded a prestigious Marie Skłodowska-Curie Fellowship by the European Commission to pursue research at the Medical Center of the University of Freiburg in Germany. Before joining TAM, he worked at Sonata Therapeutics in the Boston area as a Principal Scientist, identifying immunotherapy biomarkers for therapeutic development.
Among his scientific achievements, Gianni created FlowAI, a widely adopted software for automated quality control of flow cytometry data, used extensively across academia and industry. As a Marie Skłodowska-Curie Fellow, he pioneered research into the tumor immune microenvironment using cutting-edge single-cell and spatial technologies. Gianni has also made major contributions to transcriptomic deconvolution, developing a method based on a comprehensive immune cell reference dataset that improved bulk tissue analysis. His participation in two computational DREAM Challenges led to top-performing methods and co-authorship on high-impact publications.
Currently, within the TAM Biosciences team he leverages large-scale multi-omic data to identify novel biomarkers and therapeutic targets in immuno-oncology and cancer research. Gianni is deeply committed to advancing biomedical science and is known for his dedication and drive to translate complex data into impactful discoveries. With a proven record of innovation, Gianni continues to influence both translational science and computational method development.
Dr. Marianna Halasi, Ph.D
Scientist II – TAM Biosciences
Marianna Halasi, Ph.D., is a highly accomplished scientist with extensive expertise in cancer biology research and preclinical drug testing. With a proven track record in both academic and industry settings, Dr. Halasi excels in leading complex research projects, leveraging her proficiency in mouse-based in vivo techniques, biochemical and molecular biology methods, and advanced immunology approaches. Her work encompasses animal models of cancer, mammalian cell culture, gene manipulation, and multi-color flow cytometry, among other cutting-edge methodologies.
Dr. Halasi earned her Ph.D. and completed her postdoctoral training at the University of Illinois, where she honed her research skills and developed a strong foundation in cancer biology. Known for her scientific creativity, robust work ethic, and exceptional organizational and communication skills, she thrives in both independent and collaborative environments. Her commitment to quality, innovation, and continued learning drives advancements in cancer research through meticulous experimentation and technology integration. Her contributions include tumor growth monitoring, tissue processing, viral particle production, and dendritic cell differentiation, positioning her as a leader in the field.
Dr. Halasi’s dedication to excellence and her ability to troubleshoot complex scientific challenges make her an invaluable asset to the TAM Center’s mission of advancing transformative medical research.
Wai Yang
Senior Data Engineer – TAM Biosciences
Wai Yang is an accomplished Data Engineer with over eight years of experience designing and implementing large-scale data pipelines, automating cloud-based workflows, and optimizing data infrastructure. With deep expertise in AWS, Infrastructure as Code, and data warehousing, Wai excels at harmonizing complex datasets in alignment with FAIR principles to deliver scalable, efficient solutions that advance cutting-edge research.
Wai holds a B.S. in Chemistry and Chemical and Biomolecular Engineering from New York University, where they developed a strong foundation in scientific and computational methodologies. Currently, Wai serves as a Senior Data Engineer at a leading therapeutics company, where they have architected event-driven AWS infrastructure, deployed RNASeq and scRNASeq pipelines using Nextflow and HealthOmics, and centralized datasets through Benchling to support research platforms. Their innovative contributions include developing a chatbot powered by FastAPI, AWS Bedrock, and Claude LLMs to organize scientific literature into a centralized knowledge base, as well as leading teams to create real-time data visualization platforms with QuickSight, Tableau, and Dash.
Previously, Wai held roles in computational biology and fermentation, where they analyzed metabolomic data, built clinical data schemas, and developed dashboards to inform research on metabolic modulators. Proficient in Python, R, SQL, and tools like Databricks, Docker, and Tableau, Wai combines technical expertise with strong communication skills to bridge scientific and business needs.
Passionate about skiing, hiking, rock climbing, and brewing kombucha, Wai brings creativity and dedication to both their professional and personal pursuits. At the TAM Center, Wai’s innovative approach to data engineering continues to drive transformative advancements in medical research.
TAM Scientific Advisory Board
Michael N. Liebman, Ph.D.
Michael N. Liebman, Ph.D. is the Managing Director of IPQ Analytics, LLC and of Strategic Medicine, Inc, and Strategic Medicine, BV (the Hague, NL) after serving as the Executive Director of the Windber Research Institute from 2003-2007. He is also an Adjunct Professor of Pharmacology and Physiology at Drexel College of Medicine and Adjunct Professor of Drug Discovery at First Hospital of Wenzhou Medical University. Previously, he was Director, Computational Biology and Biomedical Informatics at the University of Pennsylvania Cancer Center from 2000-2003. He served as Global Head of Computational Genomics at Roche Pharmaceuticals, Director of Bioinformatics and Pharmacogenomics at Wyeth Pharmaceuticals, and Director of Genomics for Vysis, Inc. He co-founded Prosanos, Inc (now United BioSource) (2000). He was on the faculty of Mount Sinai School of Medicine in Pharmacology and Physiology/Biophysics. He serves on 14 scientific advisory boards and is on the Board of Directors and chairs the Science Committee of the Nathaniel Adamczyk Foundation for Pediatric ARDS, and is an Advisor to the American Heart Association Science and Technology Accelerator.
Michael is Chair of the Informatics Program of the PhRMA Foundation, Chair of its new program in Translational Medicine and Therapeutics, and a PhRMA Scientific Advisory Board member. He is on the Advisory Board of the International Society for Translational Medicine and on the Editorial Board for the Journal of Translational Medicine, for Clinical and Translational Medicine and for Molecular Medicine and Therapeutics, and the International Park for Translational Biomedicine (Shanghai). He is an Invited Professor at the Shanghai Center for Bioinformatics Technology. His research focuses on computational models of disease progression stressing risk detection, disease process and pathway modeling and analysis of lifestyle interactions and causal biomarker discovery and focuses on moving bedside problems into the research laboratory to improve patient care and quality of life. Recent activities also include computational approaches to disease modeling, patient and disease stratification, drug safety, animal testing reduction, genomic data use in healthcare, and qualitative and quantitative risk assessment in healthcare and the life sciences.
Dr. Phillip S. Kim Ph.D.
Dr. Kim was awarded the human genetics fellowship by the National Institute of Health (NIH) at the Cedar Sinai Medical Center. His research focused on the development of gene-therapy model via hematopoietic-stem cell mediated gene transfer and the development of ‘Geno-dynamics’ system to investigate gene function.
At Prometheus he led oncology and gastroenterology research teams to develop technologies, platforms and services for personalized/ targeted diagnostic applications with prognostic, predictive and monitoring utilities for oncology and autoimmune diseases.
His work included managing planning & execution of technical projects, clinical trials, science and technology communications, research collaborations & KOL (Key Opinion Leader) relationships, and publications.
He is the inventor of the immune pod which is positioned to address critical unmet need in oncology clinic by activating patient’s autologous immune cells specific for individual’s tumor for effective and safe cellular therapy without complex cellular manipulation. Minimally invasive approach using ‘Immuno-Pod’ maximizes tumor specific immune cell activation by exposing otherwise inaccessible tumor in vivo to contiguous ‘synthetic met’ ex vivo seamlessly integrated for each patient.
Dr. Kim’s valuable insight at TAM Center will help guide decisions for precision medicine and specific immune responses for all patients.